This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chan, A. W. Search for Related Content PubMed PubMed Citation Articles by Chan, A. W.

Triple antiplatelet therapy during percutaneous coronary intervention is associated withimproved outcomes including one-year survival

Results from the do tirofiban and reoprogive similar efficacy outcome trial (TARGET)

Albert W. Chan, MD^*, David J. Moliterno, MD^,*, Peter B. Berger, MD, Gregg W. Stone, MD, Peter M. DiBattiste, MD^||, Steven L. Yakubov, MD^¶, Shelly K. Sapp, MS^#, Kathy Wolski, MPH^#, Deepak L. Bhatt, MD, Eric J. Topol, MD TARGET Investigators^**

^* Department of Cardiology, Ochsner Clinic Foundation, New Orleans, Louisiana, USA
Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Division of Cardiology, Mayo Clinic Foundation, Rochester, Minnesota, USA
Lenox Hill Heart and Vascular Institute, New York, New York, USA
^|| Merck, West Point, Pennsylvania, USA
^¶ Riverside Methodist Hospital, Columbus, Ohio, USA
^# Department of Biostatistics and Epidemiology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA

View larger version (21K): [in a new window]   Figure 1 Kaplan-Meier curves of 30-day composite of death, nonfatal myocardial infarction (MI), and urgent target vessel revascularization (TVR) in patients according to clopidogrel pretreatment and assignment of glycoprotein IIb/IIIa inhibitors. The clinical benefit of clopidogrel pretreatment was present regardless of which IIb/IIIa agent was used. Abciximab was superior to tirofiban in terms of 30-day composite end point; however, the extent appears attenuated in the presence of clopidogrel pretreatment.

View larger version (20K): [in a new window]   Figure 2 Kaplan-Meier curves of composite of death and nonfatal myocardial infarction (MI) to six months, based on the use of clopidogrel pretreatment and assignment of glycoprotein IIb/IIIa inhibitors.